[Pubmed] Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6512
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of

Message par RSS-Bot »


Clin Chim Acta. 2025 Apr 24:120330. doi: 10.1016/j.cca.2025.120330. Online ahead of print.

ABSTRACT

BACKGROUNDS: Myasthenia gravis (MG) is an autoimmune disease predominantly caused by anti-acetylcholine receptor antibodies (AChR-Abs). In this study, the relationship between MG relapse and AChR-Abs concentration were investigated.

METHODS: We retrospectively reviewed the clinical records of 41 patients with AChR-Abs-positive MG. Data collected included age, sex, MG status within 12 months (untreated status, UTMG; recurrence status, RCMG), MG subgroups, QMGs, AChR-Abs concentration and treatments. The relative change rate (RCR) of AChR-Abs concentration was calculated as: RCR(%)=(AChR-Abs-AChR-AbsUTMG)/AChR-AbsUTMG/month*100. ROC curve analysis and binary logistic regression analyses were used to evaluate the association between these factors and MG recurrence.

RESULTS: Within 12 months, 12 patients experienced a recurrence (RCMG). A weak correlation was observed between AChR-Abs level in UTMG and QMGs (r = 0.336, p = 0.032). MG subgroups, QMGs, AChR-Ab levels and RCR differed significantly between RCMG and non-RCMG group. Single factor ROC curves indicated that AChR-Abs concentration, RCR and MG subgroups were related to MG recurrence (AUC = 0.724, 0.736, 0.736). Combining with RCR and MG subgroups, the ROC yielded an AUC of 0.899, demonstrating high sensitivity and specificity.

CONCLUSION: RCR of AChR-Abs was correlated with MG progression, and repeated AChR-Abs measurements can assist in monitoring disease status and guiding therapeutic decision-making.

PMID:40286896 | DOI:10.1016/j.cca.2025.120330


Source: https://pubmed.ncbi.nlm.nih.gov/4028689 ... t9+e462414
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »